SBIR/STTR Research Award

Research and Development of optimal dosing and formulation of PM-208 for AF field use

Award identifier 84cfb70554b7dfcd1943472fe547afd5634d7c45f2985747e3a5acb10ee78008Awarding agency Department of Defense · Air Force

Award amount

$1,799,322

Program and phase

STTR · Phase II

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Air Force
Recipient company
PERFUSION MEDICAL LLC
Proposal award date
2024-02-08
Contract end date
2025-11-07
UEI
XEDJGXP1K889
Solicitation number
X23.D
Topic code
AFX23D-TCSO1

Research abstract

Up to 90% of battlefield fatalities are due to hemorrhagic shock– a type of shock caused by heavy blood loss leading to inadequate blood flow to the body’s tissues, ultimately leading to tissue death due to lack of oxygen in the cells.  With the real possibility that the United States could be at war in the next two years, the Military Health System (MHS) is preparing for the next conflict: "We're worried about future casualties because those distances [to hospitals] are so great," said Air Force Col Stacy Shackelford, former Chief of the Joint Trauma System. The current standards of care for hemorrhagic shock (intravenous infusion of normal saline or whole blood) is falling flat as prehospital mortality remains high as neither address the underlying vascular constriction limiting blood supply to critical organ issues, and whole blood product is a scarce resource in battlefield medicine.  Lack of treatment options has prompted tactical combat casualty care (TCCC) groups across the Air Force to research “far-forward blood, blood components, and blood substitutes… that are portable and shelf stable.”  A novel intravenous solution, PEG-20k/8k, by Perfusion Medical stands to fill this battlefield treatment gap by providing critical and life-saving pre-hospital, shelf-stable treatments to be used for hemorrhagic shock in the field. With development at Virginia Commonwealth University (VCU) funded by over $12M from the U.S. Army, PEG-20k/8k has already been de-risked in 12 published animal trials, and demonstrated safety and efficacy in animal models to improve survival to up to 24 hours. Once FDA approved, this PEG-20k/8k product will be the first drug to specifically address the vascular constriction causing rapid tissue death in hemorrhagic shock. Now, Perfusion Medical is partnering with vascular surgeon, Dr. Todd Rasmussen (Col Ret, USAF), at the Mayo Clinic to further develop PEG-20k/8k to extend military trauma care’s critical “golden hour”-- where definitive medical attention is truly life saving–  into the “golden day” to save lives and limbs in impending near-peer conflicts. ???????

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $5,377,375. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II, Phase II

Agencies: Department of Defense, Department of Health and Human Services

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.